Dose-effect research using nanopatch to deliver siRNA in the inhibition of HPV gene expression.
- Author:
Zhuo XIONG
;
Xiaojing DONG
;
Peiwen SUN
;
Ying ZHANG
- Publication Type:Journal Article
- MeSH:
Animals;
Apoptosis;
DNA-Binding Proteins;
genetics;
Female;
Gene Expression Regulation, Viral;
HeLa Cells;
Humans;
Mice;
Mice, Nude;
Nanostructures;
administration & dosage;
Oncogene Proteins, Viral;
genetics;
Papillomaviridae;
genetics;
RNA, Small Interfering;
administration & dosage;
Transfection;
Uterine Cervical Neoplasms;
therapy;
Xenograft Model Antitumor Assays
- From:
Journal of Biomedical Engineering
2013;30(6):1283-1289
- CountryChina
- Language:Chinese
-
Abstract:
Hela is the cell line of adenocarcinoma of the uterine cervix, and human papillomavirus (HPV) 18 shows positive. We delivered siRNA with target specifically to HPV18 E7 mRNA into nude mice Hela tumor xenografts by nanopatch to inhibit the HPV gene expression, and further to study the superiority, the best action time and concentration of siRNA of using nanopatch to transfer siRNA in vivo. We designed siRNA that target specifically to HPV18 E7 mRNA (siE7) and checked the effect of siE7 in vitro. Tumor xenografts were transfected with siE7 and GenEscort III by nanopatch. Expression of HPV18 E7 mRNA and protein were detected 0 hours, 24 hours, 48 hours, 72 hours after transfection with PT-PCR and Western blot, and the best action time was analyzed using nanopatch to thansfect siRNA in vivo. We transfected GenEscort III and siE7 of Different concentration into tumor xenografts respectively by nanopatch and intraperitoneal injection. Expression of HPV18 E7 mRNA and protein was detected 72 hours after transfection by PT-PCR and Western blot, to analyze the best action concentration of siRNA and the superiority of using nanopatch to thansfect siRNA in vivo. The results proved that SiE7was efficient to inhibit expression of HPV18 E7 mRNA and to advance Hela apoptosis in vitro. SiE7 transfected by nanopatch into xenografts could inhibit effectively expression of HPV18 E7 mRNA and protein. The best action time and concentration of siRNA of using nanopatch to thansfect siRNA in vivo are 72 hour post-transfection and 2 micromol/L siE7. To compare intraperitoneal injection in delivering siRNA in vivo, the effect of nanopatch is very predominant. It can be well concluded that Nanopatch can effectively transfer siRNA in vivo, which can effectively inhibit the HPV gene expression.
